Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
Clinicians highlight the need to educate patients about warning signs
Combination therapy demonstrates effectiveness in first-line treatment setting
Research indicates strong rationale for expanding trial eligibility criteria
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dedicated investigators and clinicians bring expertise in drug development and flexible study design
Timing of adjuvant immunotherapy unclear for maximum overall survival
Forecasting tool outperforms individual biomarkers
An underappreciated immune-related adverse event
Study finds 10-month survival difference
Effects of microbiome dysbiosis on pediatric cancer and treatment